Head-to-head evidence
HBI-2376 vs JAB-3312
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: SHP2 · full Non-Small Cell Lung Cancer pipeline
HBI-2376
Developed by HUYABIO International, LLC.
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: December 2026 · NCT05163028 (registry estimate)
JAB-3312
Developed by Jacobio Pharmaceuticals
NCT04720976 · Phase 1/2 · completed
The study treated participants in several open-label combination cohorts without randomization or a comparator arm; 58 participants were enrolled across dose-escalation and dose-expansion groups. Although the planned primary outcomes included clinical measures such as objective response, progression-free survival, and overall survival, no results are posted, so it is not possible to determine whether any endpoint was met.
Next expected readout: March 2027 · NCT05288205 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: HBI-2376's landscape · JAB-3312's landscape